{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T07:46:46Z","timestamp":1761896806688},"reference-count":51,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2018,9]]},"abstract":"<jats:sec>\n            <jats:title>Purpose of review<\/jats:title>\n            <jats:p>We aim to summarize the current knowledge on the treatment of elderly Hodgkin lymphoma patients with a focus on evidence from clinical trials and novel drugs.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Recent findings<\/jats:title>\n            <jats:p>For elderly Hodgkin lymphoma patients above 60 years without precluding comorbidities a curative treatment approach is warranted. Early favorable stage patients should receive two cycles of multiagent chemotherapy followed by 20 Gy localized radiotherapy. Early unfavorable stage patients should receive four cycles of multiagent chemotherapy followed by 30 Gy localized radiotherapy. For advanced stage patients six cycles of multiagent chemotherapy can be recommended and should be followed by localized radiotherapy on residual disease manifestations. Relapsed or refractory patients should be treated in an individually tailored approach that considers both the patient's objectives and comorbidities. The antibody\u2013drug conjugate brentuximab vedotin is a very effective option for elderly patients with a high response rate albeit limited durability. Anti-programed cell death protein 1 antibodies might also be effective in elderly Hodgkin lymphoma patients with a mechanism of action distinct from chemotherapy.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Summary<\/jats:title>\n            <jats:p>In conclusion, the goal of treatment in newly diagnosed elderly Hodgkin lymphoma patients is curative whenever possible and prospective and retrospective evidence has shown that this is feasible for all disease stages with a variety of multiagent chemotherapy regimen. Relapsed and refractory elderly Hodgkin lymphoma patients can mostly only be treated with the goal of palliation. However, it remains to be seen if novel substances and new combination regimen are able to change that.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/cco.0000000000000464","type":"journal-article","created":{"date-parts":[[2018,7,11]],"date-time":"2018-07-11T22:27:41Z","timestamp":1531348061000},"page":"308-316","source":"Crossref","is-referenced-by-count":16,"title":["Hodgkin lymphoma in elderly patients"],"prefix":"10.1097","volume":"30","author":[{"given":"Sven","family":"Borchmann","sequence":"first","affiliation":[{"name":"Department I of Internal Medicine, German Hodgkin Study Group (GHSG)"},{"name":"Else Kr\u00f6ner Forschungskolleg Clonal Evolution in Cancer, University Hospital of Cologne"},{"name":"Center for Molecular Medicine Cologne, University of Cologne, Cologne, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andreas","family":"Engert","sequence":"additional","affiliation":[{"name":"Department I of Internal Medicine, German Hodgkin Study Group (GHSG)"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Boris","family":"B\u00f6ll","sequence":"additional","affiliation":[{"name":"Department I of Internal Medicine, German Hodgkin Study Group (GHSG)"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-20230901","doi-asserted-by":"crossref","first-page":"2790","DOI":"10.1016\/S0140-6736(17)32134-7","article-title":"PET-guided treatment in patients with advanced-stage Hodgkin's lymphoma (HD18): final results of an open-label, international, randomised phase 3 trial by the German Hodgkin Study Group","volume":"390","author":"Borchmann","year":"2018","journal-title":"Lancet"},{"key":"R2-20230901","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1182\/blood-2010-08-302604","article-title":"Progress in Hodgkin lymphoma: a population-based study on patients diagnosed in Sweden from 1973\u20132009","volume":"119","author":"Sj\u00f6berg","year":"2012","journal-title":"Blood"},{"key":"R3-20230901","doi-asserted-by":"crossref","first-page":"2189","DOI":"10.1182\/blood-2015-11-681064","article-title":"Bleomycin in older early-stage favorable Hodgkin lymphoma patients: analysis of the German Hodgkin Study Group (GHSG) HD10 and HD13 trials","volume":"127","author":"B\u00f6ll","year":"2016","journal-title":"Blood"},{"key":"R4-20230901","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1093\/annonc\/mdl379","article-title":"Poorer outcome of elderly patients treated with extended-field radiotherapy compared with involved-field radiotherapy after chemotherapy for Hodgkin's lymphoma: an analysis from the German Hodgkin Study Group","volume":"18","author":"Klimm","year":"2006","journal-title":"Ann Oncol"},{"key":"R5-20230901","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.1200\/JCO.2012.45.4181","article-title":"ABVD in older patients with early-stage Hodgkin lymphoma treated within the German Hodgkin Study Group HD10 and HD11 Trials","volume":"31","author":"B\u00f6ll","year":"2013","journal-title":"J Clin Oncol"},{"key":"R6-20230901","doi-asserted-by":"crossref","first-page":"2819","DOI":"10.1200\/JCO.2012.47.9774","article-title":"Treatment-related mortality in patients with advanced-stage Hodgkin lymphoma: an analysis of the German Hodgkin Study Group","volume":"31","author":"Wongso","year":"2013","journal-title":"J Clin Oncol"},{"key":"R7-20230901","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.critrevonc.2008.01.013","article-title":"The changing prevalence of comorbidity across the age spectrum","volume":"67","author":"Piccirillo","year":"2008","journal-title":"Crit Rev Oncol Hematol"},{"key":"R8-20230901","doi-asserted-by":"crossref","first-page":"2913","DOI":"10.1158\/0008-5472.CAN-14-0155","article-title":"Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States","volume":"74","author":"Rahib","year":"2014","journal-title":"Cancer Res"},{"key":"R9-20230901","doi-asserted-by":"crossref","first-page":"5052","DOI":"10.1200\/JCO.2005.11.080","article-title":"Hodgkin's lymphoma in elderly patients: a comprehensive retrospective analysis from the German Hodgkin's Study Group","volume":"23","author":"Engert","year":"2005","journal-title":"J Clin Oncol"},{"key":"R10-20230901","first-page":"438","article-title":"Hodgkin's lymphoma in the elderly with special reference to type and intensity of chemotherapy in relation to prognosis","volume":"88","author":"Landgren","year":"2003","journal-title":"Haematologica"},{"key":"R11-20230901","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1111\/j.1600-0609.2005.00457.x","article-title":"An international approach to the treatment of Hodgkin's disease in the elderly: launch of the SHIELD study programme","volume":"75","author":"Proctor","year":"2005","journal-title":"Eur J Haematol"},{"key":"R12-20230901","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1093\/oxfordjournals.annonc.a057939","article-title":"Original article: treatment outcome in Hodgkin's disease in patients above the age of 60: a population-based study","volume":"2","author":"Enblad","year":"1991","journal-title":"Ann Oncol"},{"key":"R13-20230901","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1046\/j.1365-2141.2002.03815.x","article-title":"Hodgkin's disease in the elderly: a population-based study","volume":"119","author":"Stark","year":"2002","journal-title":"Br J Haematol"},{"key":"R14-20230901","doi-asserted-by":"crossref","first-page":"14903","DOI":"10.1038\/s41598-017-14805-y","article-title":"Hodgkin lymphoma has a seasonal pattern of incidence and mortality that depends on latitude","volume":"7","author":"Borchmann","year":"2017","journal-title":"Sci Rep"},{"key":"R15-20230901","doi-asserted-by":"crossref","first-page":"725219","DOI":"10.1155\/2011\/725219","article-title":"Incidence patterns and outcomes for Hodgkin lymphoma patients in the United States","volume":"2011","author":"Shenoy","year":"2011","journal-title":"Adv Hematol"},{"key":"R16-20230901","doi-asserted-by":"crossref","first-page":"2444","DOI":"10.1182\/blood-2004-09-3759","article-title":"Impact of tumor Epstein\u2013Barr virus status on presenting features and outcome in age-defined subgroups of patients with classic Hodgkin lymphoma: a population-based study","volume":"106","author":"Jarrett","year":"2005","journal-title":"Blood"},{"key":"R17-20230901","first-page":"982","article-title":"Hodgkin's lymphoma in the elderly: a different disease in patients over 60","volume":"21","author":"Klimm","year":"2007","journal-title":"Oncology (Williston Park)"},{"key":"R18-20230901","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1097\/CCO.0000000000000396","article-title":"The genetics of Hodgkin lymphoma: an overview and clinical implications","volume":"29","author":"Borchmann","year":"2017","journal-title":"Curr Opin Oncol"},{"key":"R19-20230901","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1056\/NEJMoa1000067","article-title":"Reduced treatment intensity in patients with early-stage Hodgkin's lymphoma","volume":"363","author":"Engert","year":"2010","journal-title":"N Engl J Med"},{"key":"R20-20230901","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1097\/CCO.0000000000000314","article-title":"Current developments in the treatment of early-stage classical Hodgkin lymphoma","volume":"28","author":"Borchmann","year":"2016","journal-title":"Curr Opin Oncol"},{"key":"R21-20230901","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1200\/JCO.2011.38.5807","article-title":"Dose-intensification in early unfavorable Hodgkin's lymphoma: final analysis of the German Hodgkin Study Group HD14 Trial","volume":"30","author":"von Tresckow","year":"2012","journal-title":"J Clin Oncol"},{"key":"R22-20230901","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1200\/JCO.2013.51.9298","article-title":"Omitting radiotherapy in early positron emission tomography-negative stage I\/II Hodgkin lymphoma is associated with an increased risk of early relapse: clinical results of the preplanned interim analysis of the randomized EORTC\/LYSA\/FIL H10 trial","volume":"32","author":"Raemaekers","year":"2014","journal-title":"J Clin Oncol"},{"key":"R23-20230901","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.1056\/NEJMoa1408648","article-title":"Results of a trial of PET-directed therapy for early-stage Hodgkin's lymphoma","volume":"372","author":"Radford","year":"2015","journal-title":"N Engl J Med"},{"key":"R24-20230901","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1093\/annonc\/mdh012","article-title":"VEPEMB in elderly Hodgkin's lymphoma patients. Results from an Intergruppo Italiano Linfomi (IIL) study","volume":"15","author":"Levis","year":"2004","journal-title":"Ann Oncol"},{"key":"R25-20230901","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1111\/bjh.13904","article-title":"Reduced intensity VEPEMB regimen compared with standard ABVD in elderly Hodgkin lymphoma patients: results from a randomized trial on behalf of the Fondazione Italiana Linfomi (FIL)","volume":"172","author":"Zallio","year":"2016","journal-title":"Br J Haematol"},{"key":"R26-20230901","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1080\/10428190601126610","article-title":"Standard CHOP-21 as first line therapy for elderly patients with Hodgkin's lymphoma","volume":"48","author":"Kolstad","year":"2007","journal-title":"Leuk Lymphoma"},{"key":"R27-20230901","doi-asserted-by":"crossref","first-page":"2798","DOI":"10.1182\/blood-2015-06-644336","article-title":"Phase 2 study of frontline brentuximab vedotin monotherapy in Hodgkin lymphoma patients aged 60 years and older","volume":"126","author":"Forero-Torres","year":"2015","journal-title":"Blood"},{"key":"R28-20230901","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1016\/S0360-3016(02)04596-0","article-title":"Hodgkin's disease in elderly patients (\u226560): clinical outcome and treatment strategies","volume":"56","author":"Kim","year":"2003","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"R29-20230901","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1016\/S1470-2045(13)70341-3","article-title":"Effect of initial treatment strategy on survival of patients with advanced-stage Hodgkin's lymphoma: a systematic review and network meta-analysis","volume":"14","author":"Skoetz","year":"2013","journal-title":"Lancet Oncol"},{"key":"R30-20230901","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1093\/annonc\/mdi023","article-title":"A prospectively randomized trial carried out by the German Hodgkin Study Group (GHSG) for elderly patients with advanced Hodgkin's disease comparing BEACOPP baseline and COPP-ABVD (study HD9elderly)","volume":"16","author":"Ballova","year":"2005","journal-title":"Ann Oncol"},{"key":"R31-20230901","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1200\/JCO.2012.43.4803","article-title":"Randomized phase III trial of ABVD versus Stanford V with or without radiation therapy in locally extensive and advanced-stage Hodgkin lymphoma: an intergroup study coordinated by the Eastern Cooperative Oncology Group (E2496)","volume":"31","author":"Gordon","year":"2013","journal-title":"J Clin Oncol"},{"key":"R32-20230901","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1111\/bjh.12222","article-title":"The efficacy and tolerability of adriamycin, bleomycin, vinblastine, dacarbazine and Stanford V in older Hodgkin lymphoma patients: a comprehensive analysis from the North American intergroup trial E2496","volume":"161","author":"Evens","year":"2013","journal-title":"Br J Haematol"},{"key":"R33-20230901","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1002\/1097-0142(19900401)65:7<1635::AID-CNCR2820650730>3.0.CO;2-M","article-title":"Survival of the older patient compared with the younger patient with Hodgkin's disease. Influence of histologic type, staging, and treatment","volume":"65","author":"Walker","year":"1990","journal-title":"Cancer"},{"key":"R34-20230901","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1080\/10428190290033332","article-title":"Treatment of elderly Hodgkin's lymphoma patients with a novel 5-drug regimen (ODBEP): a phase II study","volume":"43","author":"Macpherson","year":"2002","journal-title":"Leuk Lymphoma"},{"key":"R35-20230901","doi-asserted-by":"crossref","first-page":"2026","DOI":"10.1182\/blood-2009-11-253211","article-title":"Phase 2 study of BACOPP (bleomycin, adriamycin, cyclophosphamide, vincristine, procarbazine, and prednisone) in older patients with Hodgkin lymphoma: a report from the German Hodgkin Study Group (GHSG)","volume":"116","author":"Halbsguth","year":"2010","journal-title":"Blood"},{"key":"R36-20230901","doi-asserted-by":"crossref","first-page":"6292","DOI":"10.1182\/blood-2011-07-368167","article-title":"Phase 2 study of PVAG (prednisone, vinblastine, doxorubicin, gemcitabine) in elderly patients with early unfavorable or advanced stage Hodgkin lymphoma","volume":"118","author":"B\u00f6ll","year":"2011","journal-title":"Blood"},{"key":"R37-20230901","doi-asserted-by":"crossref","first-page":"2829","DOI":"10.1182\/blood-2017-06-787200","article-title":"Frontline brentuximab vedotin in combination with dacarbazine or bendamustine in patients aged \u226560 years with HL","volume":"130","author":"Friedberg","year":"2017","journal-title":"Blood"},{"key":"R38-20230901","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1056\/NEJMoa1708984","article-title":"Brentuximab vedotin with chemotherapy for stage III or IV Hodgkin's lymphoma","volume":"378","author":"Connors","year":"2018","journal-title":"N Engl J Med"},{"key":"R40-20230901","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.1016\/S0140-6736(11)61940-5","article-title":"Reduced-intensity chemotherapy and PET-guided radiotherapy in patients with advanced stage Hodgkin's lymphoma (HD15 trial): a randomised, open-label, phase 3 noninferiority trial","volume":"379","author":"Engert","year":"2012","journal-title":"Lancet"},{"key":"R41-20230901","doi-asserted-by":"crossref","first-page":"4431","DOI":"10.1200\/JCO.2013.49.8246","article-title":"Relapsed Hodgkin lymphoma in older patients: a comprehensive analysis from the German Hodgkin Study Group","volume":"31","author":"B\u00f6ll","year":"2013","journal-title":"J Clin Oncol"},{"key":"R42-20230901","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1016\/S1470-2045(16)30167-X","article-title":"Nivolumab for classical Hodgkin's lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial","volume":"17","author":"Younes","year":"2016","journal-title":"Lancet Oncol"},{"key":"R43-20230901","doi-asserted-by":"crossref","first-page":"3733","DOI":"10.1200\/JCO.2016.67.3467","article-title":"Programmed death-1 blockade with pembrolizumab in patients with classical Hodgkin lymphoma after brentuximab vedotin failure","volume":"34","author":"Armand","year":"2016","journal-title":"J Clin Oncol"},{"key":"R44-20230901","doi-asserted-by":"crossref","first-page":"2275","DOI":"10.1080\/10428194.2017.1300898","article-title":"Novel agents in classical Hodgkin lymphoma","volume":"58","author":"Borchmann","year":"2017","journal-title":"Leuk Lymphoma"},{"key":"R45-20230901","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1038\/bmt.2010.294","article-title":"High-dose chemotherapy and auto-SCT in elderly patients with Hodgkin's lymphoma","volume":"46","author":"Puig","year":"2011","journal-title":"Bone Marrow Transplant"},{"key":"R46-20230901","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1111\/j.1365-2141.2009.07963.x","article-title":"Lenalidomide in patients with refractory or multiple relapsed Hodgkin lymphoma","volume":"148","author":"B\u00f6ll","year":"2010","journal-title":"Br J Haematol"},{"key":"R47-20230901","doi-asserted-by":"crossref","first-page":"5119","DOI":"10.1182\/blood-2011-07-362475","article-title":"A phase 2 multicenter study of lenalidomide in relapsed or refractory classical Hodgkin lymphoma","volume":"118","author":"Fehniger","year":"2011","journal-title":"Blood"},{"key":"R48-20230901","doi-asserted-by":"crossref","first-page":"2615","DOI":"10.1200\/JCO.2000.18.13.2615","article-title":"Gemcitabine in the treatment of refractory Hodgkin's disease: results of a multicenter phase II study","volume":"18","author":"Santoro","year":"2000","journal-title":"J Clin Oncol"},{"key":"R49-20230901","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1016\/S0959-8049(97)89029-6","article-title":"Trofosfamide as a salvage treatment with low toxicity in malignant lymphoma. A phase II study","volume":"33","author":"Helsing","year":"1997","journal-title":"Eur J Cancer"},{"key":"R50-20230901","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1111\/j.1532-5415.1995.tb06377.x","article-title":"Validation of the cumulative illness rating scale in a geriatric residential population","volume":"43","author":"Parmelee","year":"1995","journal-title":"J Am Geriatr Soc"},{"key":"R51-20230901","doi-asserted-by":"crossref","first-page":"1418","DOI":"10.1016\/S0140-6736(14)61469-0","article-title":"Omission of dacarbazine or bleomycin, or both, from the ABVD regimen in treatment of early-stage favourable Hodgkin's lymphoma (GHSG HD13): an open-label, randomised, noninferiority trial","volume":"385","author":"Behringer","year":"2015","journal-title":"Lancet"},{"key":"R52-20230901","doi-asserted-by":"crossref","first-page":"2228","DOI":"10.1002\/cncr.23422","article-title":"Prednisone, etoposide, procarbazine, and cyclophosphamide (PEP-C) oral combination chemotherapy regimen for recurring\/refractory lymphoma: low-dose metronomic, multidrug therapy","volume":"112","author":"Coleman","year":"2008","journal-title":"Cancer"}],"container-title":["Current Opinion in Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/00001622-201809000-00006","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T07:00:29Z","timestamp":1693551629000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00001622-201809000-00006"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,9]]},"references-count":51,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2018]]}},"URL":"https:\/\/doi.org\/10.1097\/cco.0000000000000464","relation":{},"ISSN":["1040-8746","1531-703X"],"issn-type":[{"value":"1040-8746","type":"print"},{"value":"1531-703X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,9]]}}}